Overview

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2022-12-22
Target enrollment:
Participant gender:
Summary
This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage III non-small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shandong Cancer Hospital and Institute